Literature DB >> 8637208

Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma.

I Takanami1, T Imamuma, T Hashizume, K Kikuchi, Y Yamamoto, T Yamamoto, S Kodaira.   

Abstract

We stained resected specimens from 117 patients with pulmonary adenocarcinoma for insulin-like growth factor-II (IGF-II) by the avidin-biotin-peroxidase (ABC) method and evaluated the usefulness of IGF-II as a prognostic factor. The patients were classified into the IGF-II (+) groups showing staining of 1% or more cancer cells (60 patients) and the IGF-II (-) groups showing staining of <1% (57 patients). The 5-year survival rate was 22% in the IGF-II (+) group and 54% in the IGF-II (-) group (P<0.01). Our results suggest the usefulness of IGF-II stainability as a prognostic factor of pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637208     DOI: 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

2.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

3.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

4.  Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.

Authors:  Teresa Moran; Enriqueta Felip; Vicki Keedy; Hossein Borghaei; Frances A Shepherd; Amelia Insa; Holly Brown; Timothy Fitzgerald; Sriram Sathyanarayanan; John F Reilly; David Mauro; Karl Hsu; Li Yan; David H Johnson
Journal:  Exp Hematol Oncol       Date:  2014-11-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.